Want to see AVIR full AI Analyst Report?
Top Page
Atea Pharmaceuticals
(NASDAQ:AVIR)
Select Model
Select Model
Rating:60Neutral
Price Target:
$5.50
▲(1.29% Upside)
Action:Reiterated
Date:08/19/26
The score is held back primarily by weak financial performance—no revenue, large ongoing losses, and substantial cash burn—despite low leverage. Offsetting that, technicals are supportive with the stock above major moving averages and positive momentum indicators, and the latest earnings call was positive on clinical progress and a defined regulatory path, though funding and timing risks remain meaningful.
Positive Factors
Phase 3 Clinical Validation
Successful Phase 3 results materially reduce clinical risk for the lead HCV program. Non-inferior efficacy and comparable safety provide a credible foundation for regulatory review and potential commercialization, subject to the remaining global study.
Negative Factors
No Recurring Product Revenue
Atea has not established a recurring commercial revenue base, leaving its financial outlook dependent on future regulatory success and launch execution. Persistent losses also limit visibility into when the business can become self-funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 Clinical Validation
Successful Phase 3 results materially reduce clinical risk for the lead HCV program. Non-inferior efficacy and comparable safety provide a credible foundation for regulatory review and potential commercialization, subject to the remaining global study.
Read all positive factors
Atea Pharmaceuticals (AVIR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$441.93M
Dividend YieldN/A
Average Volume (3M)331.21K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue GrowthN/A
EPS Growth-29.71%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.08
Shares Outstanding80,204,700
10 Day Avg. Volume266,515
30 Day Avg. Volume331,208
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside28.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.93
Revenue Forecast (FY)N/A
Atea Pharmaceuticals Business Overview & Revenue Model
Company Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a n...
How the Company Makes Money
Atea is a clinical-stage company and, based on publicly available information, it has not established a recurring commercial revenue base from selling approved products. Its cash inflows have primarily been associated with collaboration-related pa...
Atea Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveyed several material positive developments: a successful Phase 3 (CBEYOND) meeting primary and secondary endpoints with a favorable safety profile, rapid global enrollment and a clear development/regulatory path (C‑FORWARD readout early Q1 2027 and potential NDA in Q2 2027), a promising commercial proposition supported by market research, manufacturing readiness, and a new HEV first‑in‑human program. Offsetting risks include modest numeric SVR differences versus the comparator despite non‑inferiority, persistent adherence and loss‑to‑follow‑up challenges in real‑world populations, finite cash runway through 2027 (raising potential funding needs), and policy/pricing and regulatory timing uncertainties. Overall, the positives—clinical proof of concept, program momentum, and commercial preparedness—outweigh the headwinds, though execution and timing risks remain.Positive Updates
Positive Phase 3 CBEYOND Top-Line Results
CBEYOND met both primary and secondary endpoints with bemrusasvir demonstrating statistical non-inferiority to sofosbuvir/velpatasvir (Epclusa). MITT SVR24 (cure) was 93.9% for bemrusasvir vs 94.8% for Epclusa (within the pre-specified 5% non-inferiority margin; trial powered at 90%). Non-cirrhotic MITT SVR24: 93.5% vs 94.6%; compensated cirrhosis SVR24: 95.4% in both arms. Virologic failure rates were low and comparable; safety profile comparable with no serious adverse events attributed to bemrusasvir and no deaths in the bemrusasvir arm.
Negative Updates
Slightly Lower SVR Rates Versus Comparator (Numeric Differences)
Although non‑inferiority was met, absolute MITT SVR24 for bemrusasvir (93.9%) was numerically below sofosbuvir/velpatasvir (94.8%); non‑cirrhotic MITT was 93.5% vs 94.6%. These small numeric gaps may be discussed by stakeholders despite statistical non‑inferiority.
Read all updates
Q2-2026 Updates
Positive
Negative
Positive Phase 3 CBEYOND Top-Line Results
CBEYOND met both primary and secondary endpoints with bemrusasvir demonstrating statistical non-inferiority to sofosbuvir/velpatasvir (Epclusa). MITT SVR24 (cure) was 93.9% for bemrusasvir vs 94.8% for Epclusa (within the pre-specified 5% non-inferiority margin; trial powered at 90%). Non-cirrhotic MITT SVR24: 93.5% vs 94.6%; compensated cirrhosis SVR24: 95.4% in both arms. Virologic failure rates were low and comparable; safety profile comparable with no serious adverse events attributed to bemrusasvir and no deaths in the bemrusasvir arm.
Read all positive updates
Company Guidance
The company reiterated clear near‑term guidance: cash and marketable securities were ~$220.0 million at June 30, 2026 with a cash runway through 2027; C‑FORWARD is fully enrolled (>880 patients across 17 countries) with top‑line results expected in early Q1 2027 and, pending positive results, an NDA submission anticipated in Q2 2027; the first‑in‑human AT‑587 Phase 1 was initiated in July 2026 with hepatitis E proof‑of‑concept targeted in 2027; management expects a mid‑2028 launch with a short time to profitability thereafter. Clinical and commercial metrics supporting that guidance include C‑BEYOND meeting primary and secondary endpoints (MITT SVR 93.9% for bemrusasvir vs 94.8% for sofosbuvir/velpatasvir; non‑cirrhotic MITT 93.5% vs 94.6%; compensated cirrhosis 95.4% in both arms), a trial powered at 90% with a 5% non‑inferiority margin, enrollment across ~120 U.S./Canadian sites, market research showing 76% of high‑volume prescribers “extremely likely” to prescribe BEM/RZR and projected uptake of roughly 50% versus current regimens, a U.S. addressable population up to ~4 million infected (with only ~50% of newly infected treated in 2025 and ~75k untreated new infections last year), 2025 DAA net sales of $1.3B U.S./$2.6B global, peak U.S. net revenue potential >$700M (market expansion potential up to $2.5B), a focused target sales force of ~75–100, and commercial readiness items (4‑week blister packs, manufacturing and supply) supporting the planned timelines.Atea Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.37M |
| Gross Profit | -38.34M | 0.00 | -83.37M | -70.09M | -62.39M | 184.16M |
| EBITDA | -171.27M | -164.09M | -131.80M | -119.59M | -110.84M | 138.62M |
| Net Income | -165.29M | -158.35M | -168.38M | -135.96M | -115.91M | 121.19M |
Balance Sheet | ||||||
| Total Assets | 232.28M | 315.22M | 464.67M | 594.97M | 666.71M | 772.89M |
| Cash, Cash Equivalents and Short-Term Investments | 219.47M | 301.83M | 454.72M | 578.11M | 646.71M | 764.38M |
| Total Debt | 424.00K | 843.00K | 1.64M | 2.40M | 3.12M | 197.00K |
| Total Liabilities | 28.12M | 39.78M | 25.80M | 39.78M | 26.14M | 62.81M |
| Stockholders Equity | 204.16M | 275.43M | 438.87M | 555.19M | 640.57M | 710.08M |
Cash Flow | ||||||
| Free Cash Flow | -152.07M | -132.03M | -135.50M | -85.39M | -122.92M | -87.01M |
| Operating Cash Flow | -152.07M | -132.03M | -135.50M | -85.39M | -120.98M | -87.00M |
| Investing Cash Flow | 151.95M | 188.79M | 56.10M | 40.30M | -455.41M | -4.00K |
| Financing Cash Flow | -11.05M | -25.75M | 267.00K | 257.00K | 370.00K | 1.47M |
Atea Pharmaceuticals Technical Analysis
Positive
5.43
Price Trends
4.88
Positive
4.95
Positive
4.54
Positive
Market Momentum
0.19
Negative
61.18
Neutral
71.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVIR, the sentiment is Positive. The current price of 5.43 is above the 20-day moving average (MA) of 5.15, above the 50-day MA of 4.88, and above the 200-day MA of 4.54, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 61.18 is Neutral, neither overbought nor oversold. The STOCH value of 71.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVIR.
Atea Pharmaceuticals Risk Analysis
Atea Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Atea Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atea Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $441.93M | -2.62 | -64.25% | ― | ― | -29.71% | |
56 Neutral | $699.33M | -12.81 | -16.59% | ― | 67.01% | 40.54% | |
52 Neutral | $324.51M | -5.03 | -68.44% | ― | 19.49% | -4.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $180.68M | -4.94 | -74.36% | ― | 35.89% | 58.70% | |
41 Neutral | $59.27M | -1.77 | -300.90% | ― | 0.99% | -3014.75% |
* Healthcare Sector Average
AVIR
Atea Pharmaceuticals
5.45
1.98
57.06%
CDXS
Codexis
1.66
-1.06
-38.97%
HRTX
Heron Therapeutics
0.33
-1.06
-76.12%
PRQR
ProQR
2.32
0.13
5.94%
TLSA
Tiziana Life Sciences
1.08
-0.75
-40.98%
OABI
OmniAb
4.61
2.97
181.10%
Atea Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Atea Shareholders Back Directors, Auditors and Executive Pay
Positive
Jun 22, 2026
On June 18, 2026, Atea Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, with approximately 74.65% of outstanding common shares represented. Stockholders elected Jerome Adams, M.D., M.P.H., Howard Berman, Ph.D., and Barbara Dunca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.